Benzinga - by Benzinga Insights, Benzinga Staff Writer.
A substantial insider sell was reported on May 23, by Julie Smith, Director at Exelixis (NASDAQ:EXEL), based on the recent SEC filing.
What Happened: Smith's recent Form 4 filing with the U.S. Securities and Exchange Commission on Thursday unveiled the sale of 27,280 shares of Exelixis. The total transaction value is $576,153.
Exelixis shares are trading down 0.0% at $20.41 at the time of this writing on Friday morning.
Unveiling the Story Behind Exelixis Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis: Financial Performance Dissected Revenue Growth: Exelixis's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 4.02%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Holistic Profitability Examination:
- Gross Margin: The company maintains a high gross margin of 95.0%, indicating strong cost management and profitability compared to its peers.
- Earnings per Share (EPS): With an EPS below industry norms, Exelixis exhibits below-average bottom-line performance with a current EPS of 0.12.
Valuation Overview:
- Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 31.4 is lower than the industry average, indicating potential undervaluation for the stock.
- Price to Sales (P/S) Ratio: The P/S ratio of 3.5 is lower than the industry average, implying a discounted valuation for Exelixis's stock in relation to sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With a below-average EV/EBITDA ratio of 22.58, Exelixis presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Unmasking the Significance of Insider Transactions Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
Cracking Transaction Codes Navigating through the landscape of transactions, investors often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Exelixis's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.